Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2018

Open Access 01-12-2018 | Research article

Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations

Authors: John A. Reynolds, Eoghan M. McCarthy, Sahena Haque, Pintip Ngamjanyaporn, Jamie C. Sergeant, Elaine Lee, Eileen Lee, Stephen A. Kilfeather, Ben Parker, Ian N. Bruce

Published in: Arthritis Research & Therapy | Issue 1/2018

Login to get access

Abstract

Background

Patients with SLE display marked clinical and immunlogical heterogeneity. The purpose of the study was to investigate patterns of serum cytokines in patients with active and stable systemic lupus erythematosus (SLE) and to determine how they relate to clinical phenotype.

Methods

Serum levels of 10 cytokines were measured retrospectively in a cohort of patients with SLE and in healthy controls using a high-sensitivity multiplex bead array. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG-2004) indices. Logistic regression models were used to determine the association between cytokine levels and active SLE. Principal component analysis (PCA) and cluster analysis was then used to identify subgroups of patients on the basis of cytokine levels.

Results

Serum chemokine (C-X-C motif) ligand 10 (CXCL10) and CXCL13 were significantly higher in patients with SLE compared to healthy controls. Two cytokines (pentraxin-related protein (PTX3) and CXCL10) were significantly higher in patients with active disease after adjustment for potential confounding factors. Measurement of four cytokines (CXCL10, IL-10, IL-21 and PTX3) significantly improved the performance of a model to identify patients with clinically active disease. Cluster analysis revealed that the patients formed 3 distinct groups, characterised by higher levels of interferon alpha (IFNα) and B lymphocyte stimulator (BLyS) (group 1), increased CXCL10 and CXCL13 (group 2) or low levels of cytokines (group 3). Group 2 had significantly lower serum complement and higher anti-double-stranded DNA antibodies and increased prevalence of inflammatory arthritis.

Conclusions

Multiplex analysis has identified a serum cytokine signature for active SLE. Within the SLE population distinct cytokine subgroups were identified, with differing clinical and immunological phenotypes that appeared stable over time. Assessment of cytokine profiles may reveal unique insights into disease heterogeneity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2016. Clin Exp Rheumatol. 2016;34:69–76.PubMed Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2016. Clin Exp Rheumatol. 2016;34:69–76.PubMed
2.
go back to reference Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165:1548–50.CrossRefPubMed Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165:1548–50.CrossRefPubMed
3.
go back to reference Artim-Esen B, Cene E, Sahinkaya Y, Ertan S, Pehlivan O, Kamali S, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol. 2014;41:1304–10.CrossRefPubMed Artim-Esen B, Cene E, Sahinkaya Y, Ertan S, Pehlivan O, Kamali S, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol. 2014;41:1304–10.CrossRefPubMed
4.
go back to reference Ching KH, Burbelo PD, Tipton C, Wei C, Petri M, Sanz I, et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS One. 2012;7:e32001.CrossRefPubMedPubMedCentral Ching KH, Burbelo PD, Tipton C, Wei C, Petri M, Sanz I, et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS One. 2012;7:e32001.CrossRefPubMedPubMedCentral
5.
go back to reference Wu H, Zeng J, Yin J, Peng Q, Zhao M, Lu Q. Organ-specific biomarkers in lupus. Autoimmun Rev. 2017;16:391–7.CrossRefPubMed Wu H, Zeng J, Yin J, Peng Q, Zhao M, Lu Q. Organ-specific biomarkers in lupus. Autoimmun Rev. 2017;16:391–7.CrossRefPubMed
6.
go back to reference Davis LS, Hutcheson J, Mohan C. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interf Cytokine Res. 2011;31:781–9.CrossRef Davis LS, Hutcheson J, Mohan C. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interf Cytokine Res. 2011;31:781–9.CrossRef
7.
go back to reference Lee HM, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:676284.PubMedPubMedCentral Lee HM, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:676284.PubMedPubMedCentral
8.
go back to reference Yu SL, Kuan WP, Wong CK, Li EK, Tam LS. Immunopathological roles of cytokines, chemokines, signalling molecules, and pattern-recognition receptors in systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:715190.CrossRefPubMedPubMedCentral Yu SL, Kuan WP, Wong CK, Li EK, Tam LS. Immunopathological roles of cytokines, chemokines, signalling molecules, and pattern-recognition receptors in systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:715190.CrossRefPubMedPubMedCentral
9.
go back to reference Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther. 2013;15:R97.CrossRefPubMedPubMedCentral Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther. 2013;15:R97.CrossRefPubMedPubMedCentral
10.
go back to reference Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed
11.
go back to reference Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288–91.PubMed Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288–91.PubMed
12.
go back to reference Yee C-S, Farewell V, Isenberg DA, Rahman A, Teh L-S, Griffiths B, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2007;56:4113–9.CrossRefPubMedPubMedCentral Yee C-S, Farewell V, Isenberg DA, Rahman A, Teh L-S, Griffiths B, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2007;56:4113–9.CrossRefPubMedPubMedCentral
13.
go back to reference Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3:e491.CrossRefPubMedPubMedCentral Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3:e491.CrossRefPubMedPubMedCentral
14.
go back to reference Rose T, Grutzkau A, Hirseland H, Huscher D, Dahnrich C, Dzionek A, et al. IFN alpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2013;72:1639–45.CrossRefPubMed Rose T, Grutzkau A, Hirseland H, Huscher D, Dahnrich C, Dzionek A, et al. IFN alpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2013;72:1639–45.CrossRefPubMed
15.
go back to reference Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res Ther. 2014;16:R23.CrossRefPubMedPubMedCentral Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res Ther. 2014;16:R23.CrossRefPubMedPubMedCentral
16.
go back to reference Ribeiro DS, Lins CF, Galvao V, Santos WGD, Rosa G, Machicado V, et al. Association of CXCL13 serum level and ultrasonographic findings of joints in patients with systemic lupus erythematosus and Jaccoud's arthropathy. Lupus. 2018;27(6):939–46.CrossRefPubMed Ribeiro DS, Lins CF, Galvao V, Santos WGD, Rosa G, Machicado V, et al. Association of CXCL13 serum level and ultrasonographic findings of joints in patients with systemic lupus erythematosus and Jaccoud's arthropathy. Lupus. 2018;27(6):939–46.CrossRefPubMed
17.
go back to reference Greisen SR, Schelde KK, Rasmussen TK, Kragstrup TW, Stengaard-Pedersen K, Hetland ML, et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ‘window of opportunity’. Arthritis Res Ther. 2014;16:434.CrossRefPubMedPubMedCentral Greisen SR, Schelde KK, Rasmussen TK, Kragstrup TW, Stengaard-Pedersen K, Hetland ML, et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ‘window of opportunity’. Arthritis Res Ther. 2014;16:434.CrossRefPubMedPubMedCentral
18.
go back to reference Assandri R, Monari M, Colombo A, Dossi A, Montanelli A. Pentraxin 3 plasma levels and disease activity in systemic lupus erythematosus. Autoimmune Dis. 2015;2015:354014.PubMedPubMedCentral Assandri R, Monari M, Colombo A, Dossi A, Montanelli A. Pentraxin 3 plasma levels and disease activity in systemic lupus erythematosus. Autoimmune Dis. 2015;2015:354014.PubMedPubMedCentral
19.
go back to reference Skare TL, Nisihara R, Ramos GP, Utiyama SR, Messias-Reason I. Pentraxin-3 levels in systemic lupus erythematosus: association with cumulative damage but not with disease activity. Joint Bone Spine. 2015;82:466–7.CrossRefPubMed Skare TL, Nisihara R, Ramos GP, Utiyama SR, Messias-Reason I. Pentraxin-3 levels in systemic lupus erythematosus: association with cumulative damage but not with disease activity. Joint Bone Spine. 2015;82:466–7.CrossRefPubMed
20.
go back to reference Zivkovic V, Cvetkovic T, Mitic B, Stamenkovic B, Stojanovic S, Radovanovic-Dinic B, et al. Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study. Rheumatol Int. 2018;38(6):1003-8. Zivkovic V, Cvetkovic T, Mitic B, Stamenkovic B, Stojanovic S, Radovanovic-Dinic B, et al. Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study. Rheumatol Int. 2018;38(6):1003-8.
21.
go back to reference Pacheco Y, Barahona-Correa J, Monsalve DM, Acosta-Ampudia Y, Rojas M, Rodriguez Y, et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med. 2017;15:239.CrossRefPubMedPubMedCentral Pacheco Y, Barahona-Correa J, Monsalve DM, Acosta-Ampudia Y, Rojas M, Rodriguez Y, et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med. 2017;15:239.CrossRefPubMedPubMedCentral
22.
go back to reference van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–9.CrossRefPubMedPubMedCentral van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–9.CrossRefPubMedPubMedCentral
Metadata
Title
Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations
Authors
John A. Reynolds
Eoghan M. McCarthy
Sahena Haque
Pintip Ngamjanyaporn
Jamie C. Sergeant
Elaine Lee
Eileen Lee
Stephen A. Kilfeather
Ben Parker
Ian N. Bruce
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2018
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-018-1666-0

Other articles of this Issue 1/2018

Arthritis Research & Therapy 1/2018 Go to the issue